World News

The BD-Ebov trial, which is being conducted in Oxford, will evaluate the safety, tolerability and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged between 18 and 55 years.

The multi-target collaboration will integrate Insilico’s proprietary Pharma.AI platform with Bora’s automated manufacturing and development capabilities to establish a next-generation model for drug innovation.

The approval marks the first oral PCSK9 inhibitor, offering patients an alternative to injectable therapies traditionally used to reduce LDL cholesterol levels.

Fabhalta, a first-in-class complement factor B inhibitor, initially received accelerated FDA approval in 2024 to reduce proteinuria, or excess protein in the urine, a key indicator of kidney damage.

Samsung Biologics is pursuing the acquisition as demand for peptide therapeutics continues to accelerate, particularly amid the global success of GLP-1 medicines for treating obesity and type 2 diabetes.

The transaction, announced on July 3, includes Tanabe Pharma Factory’s production facilities in Onoda and Yoshitomi.

The FDA has classified the action as a Class II recall, indicating that the affected product may cause temporary or medically reversible adverse health effects, although the likelihood of serious health consequences remains low.

The approval authorises the company to collect plasma in Indonesia and process it through its global manufacturing network while the country develops its own plasma infrastructure.

The latest agreement aligns with Teva’s broader “Pivot to Growth” strategy, which focuses on strengthening its innovative medicines and biosimilars businesses through collaborations that expand its global pipeline.